



Atelerix enters agreement with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models

Partnership brings together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in preclinical research and biotech sectors

Newcastle, UK, 15th December 2025: Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has entered a partnership with Cherry Biotech, a French company specialising in organ-on-chip and organoid technologies for biomedical research.

The initial agreement will explore the integration of Atelerix's patented hydrogel technology with Cherry Biotech's advanced 3D organoid models to facilitate global extended-duration shipment. In collaboration, the companies aim to improve the reliability and consistency of transporting these temperature-sensitive materials without the complications of cold-chain logistics, enabling significant growth and expanded customer access to high-quality, human-relevant preclinical data worldwide. Through an initial 12-month trial period, both parties will validate their strategic and technical alignment, establishing the groundwork for a scalable, long-term commercial partnership.

Cherry Biotech's *in vitro* product range combine AI analysis, high-resolution live imaging and precisely controlled organoid culture to better predict the efficacy and safety of drugs, generating real life-like preclinical data. As part of the partnership, Atelerix's hydrogel technology will also be validated for the stable shipment of Cherry Biotech's recently released organoidPlate – an advanced multiwell plate with ready to use organoids for adipose tissue, breast cancer, liver and lung, which is now available for worldwide shipping.

The MoU builds on a test period whereby Cherry Biotech demonstrated strong performance of Atelerix's biosample preservation technology across multiple organ models, preserving membrane integrity and biological function at ambient or controlled temperatures.

Alastair Carrington, CEO, Atelerix, commented: *"This latest partnership with Cherry Biotech is a key step in expanding our commercial traction, broadening market reach, and increasing visibility for Atelerix's solutions. It is fantastic to work alongside such an innovative CRO, we are delighted that our preservation technology has already proven itself in delivering organoid models reliably and hassle-free to researchers worldwide. This partnership provides key validation, reinforcing the potential of ambient logistics to support the adoption of assay-ready animal model alternatives, advancing drug testing and better predicting human responses."*

Pierre Gaudriault, Chief Business Development Officer, Cherry Biotech, added: *"Partnering with Atelerix strengthens our ability to deliver cutting-edge organoid models to researchers in pharma and academia worldwide. The hydrogel preservation technology maintains cell viability for days at room temperature, removing cold-chain constraints and reducing environmental footprint. This innovation brings unprecedented convenience and reliability to our customers. In short, Atelerix is making easy global shipping for our product possible"*

ENDS


Notes to Editors:



*Alastair Carrington, CEO,
Atelerix*



*Pierre Gaudriault, Chief
Business Development Officer,
Cherry Biotech*



*Cherry Biotech's 3D Human
Mature Adipose Tissue
Organoid from an AdipoPlate*

For high-resolution images, please contact Zyme Communications.

For further information, please contact:

Alastair Carrington

Atelerix

Email: alastair.carrington@atelerix.co.uk

Zyme Communications

Jake Brown

Zyme Communications

Tel: +44(0) 7759 162 147

Email: jake.brown@zymecommunications.com

To opt out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please [click here](#).

About Atelerix www.atelerix.co.uk

Atelerix is pioneering a unique approach to non-cryogenic storage and transport of biological samples with its hypothermic preservation technology.

Derived from seaweed and inspired by the hibernation of the African four-toed pygmy hedgehog, Atelerix's hydrogel-based solutions alleviate the need for costly and energy-intensive cold chain supply. The hydrogels are designed to physically encapsulate cells and stabilise lipid membrane integrity, enabling the stable storage of cells, tissues and viruses at room temperature for up to two weeks.

To find out more, please visit www.atelerix.co.uk, and follow us on [LinkedIn](#).

About Cherry Biotech www.cherrybiotech.com

Cherry Biotech is a French company that develops products and expertise in complex 3D cell culture, like organoids or organ on chip. The product portfolio of Cherry Biotech aimed at helping researchers in pharma, academia and CRO to generate real life like preclinical data during for drug discovery and

personalised medicine. Its mission is to replace animal wherever possible by providing human physiology mimicking in vitro models..

Among its noticeable products, the OrganoidPlate provide its user with a standard multiwell plate loaded with ready to use mature and differentiated organoids. Saving up to 3 weeks in culture time, allowing the user to focus on the data generation.

In addition, Cherry Biotech's CUBIX platform enables pharmaceutical, biotech companies and healthcare providers to recreate immunocompetent human vascularized organ models and tumor microenvironments for better evaluation of their drug candidates.

By enabling the reconstruction of human 3D models that mimic human physiology and pathophysiology over several weeks, Cherry Biotech's proprietary CUBIX technology is the only solution that can convert a standard 2D multi-well plate into a 3D cell culture (Organ on Well).

To learn more: www.cherrybiotech.com/